Is Peptide Therapy Safe and Legal? FDA Status Explained

"Peptide therapy" is an umbrella term — our peptide therapy guide covers what clinics put under it.

This page is about the legal standing and the safety record.

On approval, the record splits in two.

Some peptides are FDA-approved drugs for specific conditions: tesamorelin (Egrifta WR) is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and its label says it is not for weight loss.

Bremelanotide (Vyleesi) is approved for acquired generalized hypoactive sexual desire disorder in premenopausal women. Semaglutide and tirzepatide are peptide drugs as well, and where their compounded copies stand is its own story — our guide to compounded GLP-1 rules covers it.

The wellness peptides are the other side of the split.

In the sources we reviewed, we did not find BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, MOTs-C, selank, semax or melanotan II as components of any FDA-approved drug, for any use.

Our researchers flag that as a reading of FDA's public records rather than a drug-by-drug database check, so treat it as "no approval we could find." The difference matters because an approval comes with a label — Egrifta WR's, for instance, states that it is not indicated for weight loss management — while a compounded drug has no such reviewed document behind it.

Compounded drugs skip that review.

FDA states that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before marketing, and says they should be used only when a patient's needs cannot be met by an FDA-approved drug.

So "is peptide therapy FDA-approved?" resolves the way the safety question does — yes for a few named drugs within their labels, mostly no for the products sold under the wellness label, and the compounding rules in the next section are what govern the difference.

For a peptide without an FDA approval, compounding is where federal law draws its line.

Under FD&C Act section 503A, a pharmacy or physician may compound from a bulk drug substance only if the substance has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list.

Most "wellness" peptides meet none of the three, so their legal status rests on FDA's interim enforcement policy, which sorts the nominated substances into three categories.

Category 1 means FDA is still evaluating the substance and does not currently intend to take action against a compounder using it, provided the conditions in the guidance are met.

Category 2 means FDA has identified significant safety risks and may take enforcement action.

Category 3 means the substance was nominated without enough support and is not covered by the Category 1 policy at all.

Substances nominated on or after January 7, 2025 are not placed into these categories.

The lists move, so the dates matter.

On FDA's list updated May 14, 2026, NAD, NADH, glutathione, methylcobalamin, alpha lipoic acid and vasoactive intestinal peptide — substances used in med spa IV drips and shots — sit in Category 1, meaning under evaluation, not approved.

That May 2026 update also puts ibutamoren mesylate and kisspeptin-10 in 503A Category 2, alongside cesium chloride, domperidone, germanium sesquioxide and quinacrine for intrauterine use; FDA's safety-risks page additionally lists GHRP-2, GHRP-6, ipamorelin and ibutamoren in Category 2 for 503B outsourcing facilities.

Effective April 22, 2026, FDA moved BPC-157, TB-500, CJC-1295, AOD-9604, ipamorelin (for 503A), melanotan II, MOTs-C, selank, semax and the other substances now on its "nominated but withdrawn" table out of Category 2, because the people who nominated them withdrew.

The move did not make them legal to compound routinely: none of them was placed in Category 1 or on the 503A bulks list, and FDA's safety concerns for these substances — immunogenicity, impurities, little or no human safety data — remain posted.

Next came a hearing.

FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026 to discuss adding BPC-157 (nominated for ulcerative colitis), KPV, TB-500 and MOTs-C, and then emideltide/DSIP, semax and epitalon, to the 503A bulks list.

Committee recommendations are non-binding — and as of our most recent check in October 2026, we found no source showing that any of the withdrawn peptides had been added to the bulks list.

For BPC-157, TB-500 and the other withdrawn peptides, we have no trial-based side-effect percentages to quote: FDA's posted concern for these substances is precisely that little or no human safety data exists.

What the agency documents instead is a standing concern about compounded injectable peptides: immunogenicity — immune reactions driven by peptide aggregation and peptide-related impurities — plus a lack of human safety data.

Two of the substances named in FDA's compounding review — ibutamoren and kisspeptin-10 — sit in Category 2, the significant-safety-risk tier.

Each of these signals is attached to one named substance in FDA's compounding review; none of them is a finding about "peptide therapy" as a program.

If you have already had peptide injections and feel unwell, contact the provider who treated you, and seek emergency care for severe symptoms.

A licensed provider can also set the exact substance you were given beside FDA's posted concerns and tell you what they say.

The sharpest red flag is a label, not a sales pitch: peptides sold online marked "for research purposes only" or "not for human consumption." In its warnings about unapproved GLP-1 drugs, the agency says it has issued warning letters to companies selling such products for human use, some with dosing instructions, and describes them as unapproved drugs of unknown quality that may be harmful to health.

For some molecules the agency goes past "red flag." FDA says retatrutide and cagrilintide cannot legally be used in compounding and are not in any FDA-approved drug, and that products sold "for research purposes" or "not for human consumption" containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide are illegal unapproved drugs.

A state board can draw a harder line.

Mississippi's State Board of Medical Licensure posts a joint statement that healthcare providers may not compound, administer or dispense non-FDA-approved, research-grade peptides to patients under any circumstances.

That statement belongs to Mississippi and does not transfer anywhere else — but it shows how the "research-grade" framing reads to a regulator, and it is a fair question to put to any clinic: if a peptide has no FDA approval and no Category 1 listing, the compounding-law routes described above — a USP or NF monograph, a component of an FDA-approved drug, or the 503A bulks list — are the only ones that could stand behind it, and most wellness peptides meet none of them.

Two anchors hold, whatever a clinic sells.

The first is the supply chain.

For the prescription drugs Wegovy, Zepbound and Foundayo, FDA advises getting a prescription from a licensed prescriber and filling it at a state-licensed pharmacy, and the agency flags any seller that does not require a screening and prescription.

That advice names those three drugs, but it describes a standard you can ask any clinic to meet: a named prescriber, a named pharmacy, a screening before the product.

The second anchor is who may treat you, and that is state law.

AmSpa, the medical spa association, explains this using botulinum toxin as its example: injecting a prescription drug affects living tissue, so it is the practice of medicine, restricted to a physician, an independent-practice nurse practitioner or another licensed professional acting within their scope, under rules that vary by state.

None of these questions is hostile — the second and third are answerable from FDA's public record and the first and fourth from the clinic itself, and a clinic that answers them has located itself on the legal map for you.

For the checks that apply to any med spa visit, our how to choose a med spa checklist walks through medical direction, who performs the treatment and what a legitimate consultation looks like, in order.